Coronavirus company news summary – LabCorp launches test for Covid-19, influenza and RSV – QIAGEN launches rapid Covid-19 antigen test

9 September 2020 (Last Updated September 9th, 2020 09:51)

LabCorp has launched the first testing method to test for Covid-19, influenza A/B, and respiratory syncytial virus (RSV) simultaneously. The test is expected to help the doctors regarding the treatment options for the patients. The company has applied to the US Food and Drug Administration (FDA) to provide the combined test via its Pixel by LabCorp at-home test collection kit.

CommonSpirit has opened its Reference Lab, which will increase Covid-19 testing capacity threefold for the 137 hospitals and over 1,000 care sites of the non-profit. The lab is located in Scottsdale, Arizona and will boost the Covid-19 test capacity of the country by 70,000 tests each week.

QIAGEN has planned to launch a rapid portable test to detect SARS-CoV-2 antigens in people with active infections in less than 15 minutes. It will be used to process around 30 swab samples hourly with the help of a small digital detection system. The Access Anti-SARS-CoV-2 Antigen Test is meant for environments with the need for high volume of test results that are fast and reliable.

TEAM Technologies has planned to produce a point-of-care (POC) test to aid organisations that require rapid testing for Covid-19. The company has partnered with Maxim Biomedical to produce the in-vitro diagnostic (IVD) test. Maxim produced the test as part of the NIH Rapid Acceleration of Diagnostics RADxSM initiative which was launched in April.